Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Chronic Spontaneous Urticaria Extension Study
NCT05513001Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic spontaneous urticaria (CSU) (3 arms), sponsored by Novartis. Primary endpoint: Time to first composite event (relapse UAS7 >= 16) at 24 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05513001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513001.